Oncology Network Pharmacies—
Offering patient management and access information

To learn more about what features are available to your patients, you may contact one of the network pharmacies listed below.

**Network pharmacies:**

**Accredo**  
Phone: 888-608-9010  
Fax: 888-302-1028  
www.accredco.com

**Advanced Care Scripts**  
Phone: 877-985-6337  
Fax: 866-679-7131  
www.acs-rx.com

**The Apothecary Shops**  
Phone: 877-546-5779  
Fax: 877-546-5780  
www.theapothecaryshop.com

**Axium Healthcare Pharmacy, Inc.**  
Phone: 407-804-2700  
Fax: 888-315-3270  
www.axiumhealthcare.com

**BioPlus Specialty Pharmacy Services, Inc.**  
Phone: 888-292-0744  
Fax: 800-269-5493  
www.bioplusrx.com

**Care Med**  
Phone: 877-227-3405  
Fax: 877-542-2731  
www.caremedps.com

**CuraScript, Inc.**  
Phone: 888-773-7376  
Fax: 888-773-7386  
www.curascript.com

**Diplomat Pharmacy**  
Phone: 877-977-9118  
Fax: 800-550-6272  
www.diplomatpharmacy.com

**Medfusion/Ascend**  
Phone: 888-432-2797  
Fax: 205-995-8388  
www.medfusionrx.com

**Prescription Solutions**  
Phone: 888-980-8731  
Fax: 800-853-3844  
www.prescriptionsolutions.com

**Walgreens Specialty Pharmacy**  
Phone: 888-347-3416  
Fax: 877-231-8302  
www.walgreens.com/pharmacy/specialtypharmacy

**US Bioservices**  
Phone: 877-757-0667  
Fax: 888-899-0067  
www.usbioservices.com

TEMODAR is widely available at pharmacies in and out of the Oncology network pharmacies. Check with your pharmacy to learn what features they offer patients. Merck does not support the use of any particular pharmacy, and one is not preferred over the others. Merck does not make any warranty as to the features offered by any particular pharmacy.

**Selected Important Safety Information**

- Caution should be exercised when administered to those with severe hepatic or renal impairment.
- The adverse event profile was similar in patients <65 years of age and those ≥65 years.
- The most common adverse reactions in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; rash 19%, 13%; constipation 18%, 22%; with the following important adverse events also reported: convulsions 6%, 11% and thrombocytopenia 4%, 8%.
- Of these adverse events, those grade ≥3 in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were fatigue 7%, 9%; nausea 1%, 1%; vomiting <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; rash 1%, 1%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia 3%, 4%.
- When laboratory abnormalities and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and Grade 3 or 4 platelet abnormalities, including thrombocytopenic events, occurred in 14% of patients treated with temozolomide.
- Adverse reactions reported from intravenous formulation studies that were not reported in TEMODAR Capsule studies were: pain, irritation, pruritus, warmth, swelling, and erythema at infusion site as well as the following adverse reactions: petechiae and hematoma.

Before prescribing TEMODAR, please read the accompanying Prescribing Information.

For additional copies of the Prescribing Information, call 800-672-6372, visit temodar.com, or contact your Merck representative.
Support for Your Patients
Prescribed TEMODAR at Oncology Network Pharmacies

Patient support features include:
- Compliance and case management programs
- Coordination with laboratory service providers when applicable
- 24-hour counseling services
- Educational materials and support to supplement information provided by a physician
- Information on accessing TEMODAR
- Pharmacists and nurses with up-to-date experience in managing patients who are on chemotherapy agents
- Next day delivery of medications, supplies, and refill reminder service

Indication
TEMODAR is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.

Selected Important Safety Information
- TEMODAR is contraindicated in patients who have a history of hypersensitivity (such as urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome) to any of its components, or to DTIC.
- Patients treated with TEMODAR may experience myelosuppression including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with aplastic anemia including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression. Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed.
- Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.
- TEMODAR can cause fetal harm when administered to a pregnant woman. In nursing women, a decision should be made whether to discontinue nursing or to discontinue TEMODAR, taking into account the importance of the drug to the mother. The safety and effectiveness of TEMODAR in children have not been established.
- As bioequivalence between TEMODAR Capsules and TEMODAR for Injection has been established only when TEMODAR for Injection was given over 90 minutes, infusion over a shorter or longer period of time may result in suboptimal dosing. Additionally, the possibility of an increase in infusion-related adverse reactions cannot be ruled out.
- TEMODAR Capsules should not be opened or chewed. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes.

Before prescribing TEMODAR, please read the accompanying Prescribing Information.
For additional copies of the Prescribing Information, call 800-672-6372, visit temodar.com, or contact your Merck representative.